Early-Onset ICI-Related Myocarditis Linked to Increased Mortality - Summary - MDSpire
Feature

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...

Share

A recent study presented at the AACR Annual Meeting 2026 revealed that early-onset myocarditis related to immune checkpoint inhibitors (ICIs) significantly increases the risk of fatality. Researchers, led by Dr. Hassan Mohammed Abushukair, emphasized the importance of monitoring patients during the first month of ICI therapy, identifying it as a critical period for risk assessment. The study characterized triple-M overlap syndrome (myocarditis, myositis, and myasthenia gravis), demonstrating that fatalities were more prevalent among patients with this syndrome, prompting a need for improved monitoring protocols.

Original Source(s)

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

  • by The ASCO Post Staff

  • May 4, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...